Vertex Pharmaceuticals (VRTX) reached $464.2 at the closing of the latest trading day, reflecting a -1.73% change compared to its last close.

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is one of Goldman Sachs’ top healthcare stock picks. On July 1, the European Commission approved the company’s new cystic fibrosis treatment ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has been named a 2025 Breakthroughs Innovation Celebration winner by Premier, Inc., a leading health care improvement company ...

Following our analysis of the options activities associated with Vertex Pharmaceuticals, we pivot to a closer look at the company's own performance. Where Is Vertex Pharmaceuticals Standing Right Now?

About Vertex Pharmaceuticals Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases.

Vertex Pharmaceuticals scored a major win with the EU approval of ALYFTREK, expanding its cystic fibrosis treatment access in Europe. This regulatory greenlight paves the way for stronger market ...

Vertex Pharmaceuticals said on Tuesday its next-generation cystic fibrosis treatment has won European Union approval for a rare and progressive genetic disease, expanding the company’s presence ...

Sodium channel blockers for pain: New opportunities after Vertex’s ‘watershed’ moment The success of Vertex’s opioid alternative Journavx could aid a group of biotechs that aim to take a similar ...